HC Wainwright & Co. maintains Actuate Therapeutics at Buy, lowers price target to $10 from $15

HC Wainwright & Co. kept its Buy rating on Actuate Therapeutics but reduced its price target to $10 from $15, a 33.3% cut. The new target suggests a 3405.1% upside from the Nov 13 close of $0.29.

Original reporting
Published Nov 16, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Actuate Therapeutics at Buy, lowers price target to $10 from $15 — source image
Decision brief

The 30-second read

$ACTUBearishLow
01

Why it matters

The downgrade may prompt short‑term selling but does not reflect a fundamental change in the company's operations.

02

Market read

A modest analyst downgrade with limited market impact; primarily relevant to traders holding or watching ACTU.

03

What to watch

No new corporate events; the move is purely analyst opinion.

Relevance 4/10Novelty 5/10Timing: same‑day reaction

Background

Actuate Therapeutics is a micro‑cap biotech with recent volatility; analyst coverage is sparse.

Company-level read

Ticker impact

$ACTUBearishMedium confidence
Context

HC Wainwright lowered its price target for Actuate Therapeutics to $10 from $15, indicating a bearish analyst view.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

The price‑target cut reflects reduced expectations and may trigger sell‑offs.

Market effects

Minor impact on the biotech sector; similar small‑cap stocks may see slight sentiment drag.

Limited to U.S. micro‑cap biotech investors.

Low

Counterpoint

Some investors may view the lower target as a buying opportunity if they believe the stock is undervalued.

Key entities

  • HC Wainwright & Co.

    Equity research firm that issued the price‑target cut.

  • Actuate Therapeutics

    Biotech firm whose stock is affected by the analyst downgrade.

Related articles

$ACTUMed

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

$ACTUMedAI 8/10

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.